WO2026099821 - IGG4 BINDING POLYPEPTIDES WITH IMPROVED FC FUNCTION
National phase entry is expected:
Publication Number
WO/2026/099821
Publication Date
15.05.2026
International Application No.
PCT/IB2025/061420
International Filing Date
07.11.2025
Title **
[English]
IGG4 BINDING POLYPEPTIDES WITH IMPROVED FC FUNCTION
[French]
POLYPEPTIDES DE LIAISON IGG4 AYANT UNE FONCTION FC AMÉLIORÉE
Applicants **
ABLYNX N.V.
Inventors
JAWORSKI, Julie A.
KATHURIA, Sagar V.
PARK, Sunghae
SALEMI, Megan
SUN, Victor Zhao
Priority Data
63/718,210
08.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5004 | |
| EPO | Filing, Examination, Granting | 99510 | |
| Japan | Filing, Examination, Granting | 4816 | |
| South Korea | Filing, Examination, Granting | 7793 | |
| USA | Filing, Examination, Granting | 45540 |
Total:
162,663
Contact Us
Abstract[English]
Provided herein are variant IgG4 Fc domains comprising amino acid substitutions that decrease self-interaction of a polypeptide and/or decrease aggregation.[French]
L'invention concerne des domaines Fc IgG4 variants comprenant des substitutions d'acides aminés diminuant l'auto-interaction d'un polypeptide et/ou diminuant l'agrégation.